NVIDIA and Novo Nordisk Partner to Accelerate AI-Driven Drug Discovery
NVIDIA and Novo Nordisk have announced a partnership to build customized AI models and agents to accelerate drug discovery and development processes135.
Novo Nordisk will leverage the Gefion AI Supercomputer—powered by NVIDIA DGX SuperPod technology—for large-scale data processing and high-performance computing, aiming to shorten R&D timelines and enhance healthcare innovation34.
The collaboration includes using NVIDIA’s BioNeMo generative AI platform for drug discovery and the Omniverse platform to simulate environments for developing physical AI applications2.
This multiyear agreement marks a major step in utilizing next-generation AI across Novo Nordisk’s value chain, with the aim of transforming pharmaceutical research and enabling new therapeutic discoveries3.
Industry leaders describe the opportunities for AI in pharma as 'immense,' indicating a shift toward technology-driven innovation across the drug development value chain2.
Sources:
1. https://firstwordpharma.com/story/5971298
2. https://www.fiercebiotech.com/biotech/opportunities-are-immense-novo-nordisk-signs-use-danish-supercomputer
3. https://www.prnewswire.com/news-releases/novo-nordisk-selects-gefion-ai-supercomputer-to-advance-drug-discovery-and-healthcare-innovation-302478832.html
4. https://www.pharmabiz.com/NewsDetails.aspx?aid=178436&sid=2
5. https://www.ainvest.com/news/nvidia-novo-nordisk-partner-accelerate-drug-discovery-ai-2506/